TEVA PHARMACEUTICAL INDUSTRIES LTD
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Oppenheimer initiated coverage of Viatris (VTRS) and Teva Pharmaceutical (TEVA) with Outperform ratings. Viatris has a $25 price target (~46% upside), and Teva has a $50 target (~27% upside).
Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
Oppenheimer initiated Teva Pharmaceutical (TEVA) with an outperform rating and $50 price target, citing pipeline developments and growth prospects. TEVA shares are up 98% year-over-year. Moody's upgraded Teva to investment grade, and UBS raised its price target to $48. The company reported FDA application acceptance for ecopipam and a patent settlement with Aurinia.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD). Coverage has skewed bullish: 5 bullish, 1 neutral, and 1 bearish.
Recent TEVA coverage spans financial news, insider activity and regulation.
In the last 30 days, TEVA insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($14.6M). The most active reporter was Savage Brian, Interim Chief Legal Officer, with 3 filings.
Positive rating may support a rally toward the new target.
Outperform rating may support price.
Analyst initiation with a specific $50 target and pipeline thesis can drive near-term sentiment and positioning, but it is not a new fundamental disclosure from Teva itself.
Insider sale may signal lack of confidence, but size is modest relative to market cap.
Significant insider sell may signal negative sentiment and pressure on TEVA stock.
AlphAI scores every news story that mentions TEVA with an AI model for sentiment and relevance, and aggregates insider trades from TEVA PHARMACEUTICAL INDUSTRIES LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer initiated coverage of Viatris (VTRS) and Teva Pharmaceutical (TEVA) with Outperform ratings. Viatris has a $25 price target (~46% upside), and Teva has a $50 target (~27% upside).
1 min readStifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
2 min readOppenheimer initiated Teva Pharmaceutical (TEVA) with an outperform rating and $50 price target, citing pipeline developments and growth prospects. TEVA shares are up 98% year-over-year. Moody's upgraded Teva to investment grade, and UBS raised its price target to $48. The company reported FDA application acceptance for ecopipam and a patent settlement with Aurinia.
3 min readSavage Brian (Interim Chief Legal Officer) sold 7,342 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at an average of $38.85 ($38.69–$39.14, $0.29M total) across 3 trades on 2026-09-18.
1 min readMIGNONE ROBERTO sold 367,600 indirectly-held shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $39.06 ($14.36M total) on 2026-09-18.
1 min readMayer Brown advised underwriters on Teva Pharmaceutical's $4.9 billion senior notes offering, which closed today. The firm's team included partners David Becker, Rob Mathews, and Ben Bierwirth, who recently joined Mayer Brown and have previously worked with Teva.
2 min readRussia's Federal Antimonopoly Service is investigating Teva and Grotex for potentially unfair competition by selling generic versions of Pfizer's Eliquis before its patent expires in 2027. The case involves Teva's Apixanta and Grotex's Apiklis, with the patent dispute ongoing in Russia's pharmaceutical market. Eliquis, a Pfizer-Bristol Myers Squibb drug, faces patent expirations globally, expecting generic competition.
2 min readTeva presented new data on Olanzapine LAI and UZEDY® at Psych Congress 2026. Olanzapine LAI, in Phase 3 trials, showed 56% stabilization and 4% relapse rate among stabilized participants. UZEDY® data indicated better treatment continuity and lower healthcare costs. Olanzapine LAI awaits FDA decision in Q4 2026. Both treatments use Medincell's BEPO® technology.
2 min readTeva presented new data from its phase 3 SOLARIS study on olanzapine LAI, showing 56% of participants achieved clinical stabilization. The FDA decision on the treatment is expected in Q4 2026. Teva submitted its marketing application in December 2025, accepted by the FDA in February 2026.
2 min readTeva Pharmaceutical (TEVA) reported real-world data showing UZEDY reduced emergency visits and healthcare costs for schizophrenia patients compared to other treatments. The study, presented at Psych Congress 2026, found UZEDY patients had fewer ER visits and lower monthly healthcare costs. TEVA stock closed at $38.98, down 0.54%, and was at $38.66 in after-hours trading.
2 min read
